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158Abstract: Obtaining opioids from multiple prescribers, known as doctor shopping, is 1 example of
opioid abuse and diversion. The dual mechanism of action of tapentadol could make tapentadol less
likely to be abused than other opioids. The aim of this retrospective cohort study was to compare the
risk of shopping behavior between tapentadol immediate release (IR) and oxycodone IR. Subjects ex-
posed to tapentadol or oxycodone with no recent opioid use were included and followed for 1 year.
The primary outcome was the proportion of subjects who developed shopping behavior defined as
subjects who had opioid prescriptions written by >1 prescriber with $1 day of overlap filled at $3
pharmacies. The opioids involved in the shopping episodes were assessed. A total of 112,821 subjects
were exposed to oxycodone and 42,940 to tapentadol. Shopping behavior was seen in .8% of the
subjects in the oxycodone group and in .2% of the subjects in the tapentadol group, for an adjusted
odds ratio of 3.5 (95% confidence interval, 2.8 to 4.4). In the oxycodone group, 28.0% of the shopping
events involved exclusively oxycodone, whereas in the tapentadol group, .6% of the shopping
events involved exclusively tapentadol. Results suggest that the risk of shopping behavior is substan-
tially lower with tapentadol than with oxycodone.
Perspective: The risk of opioid doctor shopping, ie, obtaining opioid prescriptions from multiple
prescribers, is lower with tapentadol than with oxycodone.
ª 2013 by the American Pain Society
Key words: Tapentadol, shopping behavior, oxycodone.ain is a significant public health problem. The 2011
Institute of Medicine report states that chronic
pain affects at least 116 million adults in the U.S.16
and that uncontrolled pain substantially reduces quality
of life and productivity.16 Opioids provide treatment for
acute and chronic pain and are increasingly prescribed
for these conditions.19 However, there is growing con-
cern about the risk of opioid abuse, misuse, diversion,7,19
and overdose.3,23,29 Diversion through family and friends
is now the greatest source of illicit opioids.3,24 ObtainingSeptember 13, 2012; Revised October 19, 2012; Accepted
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.doi.org/10.1016/j.jpain.2012.10.012opioid prescriptions from multiple prescribers, known
as doctor shopping, is a way in which opioids may be
abused and their use diverted.3
The mechanism of action of an opioid could influence
its abuse potential.20,31 Tapentadol is an opioid with 2
mechanisms of action. It activates opioid receptors and
inhibits the reuptake of norepinephrine.18 Tapentadol
has 50-fold lower affinity to the mu receptor than mor-
phine.28 Since the activation of the mu opioid receptor
is responsible for the mood alterations and the euphoria
associated with opioids, the risk of abuse associated with
tapentadol may be expected to be lower thanwith other
strong opioids. Internet monitoring, surveillance of
addiction treatment centers, and pharmacovigilance
efforts to assess the risk of misuse, abuse, and diversion
of tapentadol appear to support this view.8,9 The lower
rates of abuse observed with tapentadol compared to
oxycodone take into consideration drug availability—
the number of subjects receiving prescriptions for these
drugs.8,9
Shopping behavior has been traditionally assessed by
counting the number of prescribers or number of phar-
macies a subject visits in a specific time period.17,21,25,30
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written by different prescribers had to overlap, such a
definition of shopping behavior does not differentiate
between opioids and diuretics in that shopping
defined in this way occurs in approximately the same
proportion of opioid users and diuretic users.5 Such a
definition of shopping may incorrectly identify patients
as shoppers with deleterious consequences for under-
standing shopping behavior and evaluating interven-
tions aimed at decreasing it.
An alternative definition of shopping behavior to
differentiate opioids from diuretics requires not only
overlapping prescriptions from more than 1 prescriber
but also the filling of those prescriptions at 3 or more
pharmacies.5 In a previous study using this definition,
subjects exposed to diuretics exhibited lower frequency
of shopping behavior (.03%) than subjects exposed to
opioids (.18%).5
The aim of this study was to compare the risk of shop-
ping behavior of tapentadol immediate release (IR) with
the risk of shopping behavior of oxycodone IR.Methods
Study Design
This retrospective cohort study used the IMS LRx
database.Study Setting
The longitudinal database covers 65% of all retail
dispensing in the United States and includes all types of
pharmacies—chains, food stores, mass merchandisers,
and independent stores. From each of the pharmacies
in the panel, the database captures all prescriptions
that were dispensed, regardless of payment type. There-
fore, the LRx database includes prescriptions filled for
patients with any insurance type (commercial, Medicare,
Medicaid) or patients who pay cash. Dispensing records
are collected directly from pharmacies, which provide
encrypted patient identifiers compliant with Health In-
surance Portability and Accountability Act (HIPAA) pri-
vacy regulations.
The LRx database includes data on the de-identified
subject, the pharmacy, and the prescriber. To uniquely
identify a subject who filled prescriptions at multiple
pharmacies, a probabilistic match is performed using
a proprietary algorithmbased on encrypted, nonidentifi-
able data elements including gender, date of birth, last
name, first name, address, city, state, zip code, and payer
identification.
Unlike statewide prescription monitoring programs
(statewide electronic databases that collect data on con-
trolled substances dispensed in the state) or electronic
health care databases, LRx is not constrained by state
lines, captures filling of prescriptions paid in cash, and in-
cludes information on both the prescriber and the phar-
macy. It is unusual for health care databases to include
information on both prescriber and pharmacy, and it is
important to capture information on cash transactionsbecause approximately 45% of subjects exhibiting shop-
ping behavior pay in cash.6Participants and Interventions
We included subjects exposed to tapentadol IR or
oxycodone IR from July 2009 to December 2010 who
had not received an opioid of any type in the 3 months
before the index date. The index date was the date of
the first prescription for tapentadol IR or oxycodone
IR after June 30, 2009. Each subject was followed for
1 year from the index date.
Oxycodone IR, as a single drug, not in combination,
was selected as a comparator because it is a strong opi-
oid, is widely used, is available as IR formulation, and
was the opioid that served as an active comparator in ta-
pentadol’s efficacy trials. The only formulation of tapen-
tadol available on the market during the present study
was IR. A 1-year follow-up was deemed sufficient be-
cause in a previous study with a longer follow-up the
mean time to the first shopping episode in subjects
newly exposed to opioids was 9 months.6
We excluded subjects who filled a prescription for an
opioid other than tapentadol IR or oxycodone IR on
the index date or in the next 3 days. This exclusion was
made to ensure that subjects did not have the outcome
of interest before the study started, and to isolate the ex-
posure to the indexed opioid; ie, to decrease the likeli-
hood of introducing bias to the association of the
indexed opioid and shopping behavior.
The study was powered to detect a 50% reduction in
the risk of shopping behavior with 80% power and 5%
alpha error, assuming the risk of shopping behavior dur-
ing the follow-up period with oxycodone IR was 67/
100,000, which is the risk observed in subjects exposed
to opioids at 1 year of follow-up in a previous study
that assessed shopping behavior.5 Because fewer sub-
jects were exposed to tapentadol IR than to oxycodone
IR, we matched up to 4 oxycodone subjects, if available,
to each tapentadol subject. The choice of matching vari-
ables allowed us to control for several potentially impor-
tant potential confounders in the design rather than in
the analysis.
Each tapentadol IR-exposed subject was matched to
up to 4 randomly selected oxycodone IR-exposed
subjects by: calendar quarter and year of initial expo-
sure (index date); first 3 digits of the zip code of the
pharmacy dispensing the opioid at the index date;
age 65 years; and specialty of prescriber. The specialties
of the prescribers were categorized as 1) ‘‘Primary care,’’
for specialties such as family practice, internal medicine,
nurse practitioner, physician assistant, pediatrics,
general practice, obstetrics, and gynecology; 2) ‘‘Ortho-
pedic surgery or general surgery,’’ for orthopedic
surgery, general surgery, or orthopedic surgery of
the spine; 3) ‘‘Pain medicine,’’ for pain medicine, pain
management, physical medicine and rehabilitation,
and rheumatology; 4) ‘‘Dentistry,’’ for dentistry; 5)
‘‘Emergency medicine,’’ for emergency medicine; 6)
‘‘Addiction medicine,’’ for addiction medicine; and 7)
‘‘Other,’’ for cardiology, nephrology, plastic surgery,
160 The Journal of Pain Doctor Shopping for Tapentadol and Oxycodoneetc. This classification differentiates specialties that are
associated with low and high risk of having subjects
with opioid shopping behavior.4
Amatching ratio of 1:4 was chosen because there is lit-
tle gain in power going beyond a ratio of 4 or 5 controls
to cases.14 The matching variables were selected because
they are potential confounders or potential sources of
bias in observational studies. There is an association be-
tween the amount and type of opioids available in a geo-
graphic area and abuse in that area.2 Subjects between
19 and 64 years of age are at increased risk of developing
opioid shopping behavior compared to older subjects.6
Certain specialties have in their practices more opioid
shoppers than others, likely due to channeling of high-
risk subjects to specific specialties,4 and matching on
calendar time will control for time trends in prescriber
practices or shopping risk.
To ascertain the duration of follow-up in the database,
we searched prescriptions for any medication during the
year of follow-up.Main Outcome Measurements
The primary outcome was prespecified as the propor-
tion of subjects who developed shopping behavior at
any time during the 1 year of follow-up. Shopping be-
havior was defined as >1 prescription by $2 different
prescribers with$1 day of overlap and filled at$3 phar-
macies. All of these conditions had to be met.
Secondary outcomes, also prespecified, were the num-
ber of shopping episodes during the year of follow-up,
time to first shopping episode, and whether the dispens-
ing in the shopping episodes were for the same opioid or
not. To count shopping episodes, each time a new pre-
scription was observed the rule for shopping behavior
was checked, and if the criteria for shopping behavior
were met a new episode was counted. The shopping
episodes were classified as 1) episodes in which all the
prescriptions were for the indexed opioid; 2) episodes
in which none of the prescriptions were for the indexed
opioid; and 3) episodes in which some of the prescrip-
tions were for the indexed opioid.
As a post hoc analysis, the risk of developing ‘‘heavy’’
shopping behavior was compared between the subjects
exposed to tapentadol IR and the subjects exposed to
oxycodone IR. A subject was considered a heavy shopper
if he or she had$5 shopping episodes in 1 year. This def-
inition of heavy shoppers has been used previously.5,6Additional Potential Confounders
In addition to the matching variables (time of the
exposure, geographic area, specialty of the prescriber,
and age), we considered gender, any exposure to benzo-
diazepines during the 3 months before the index date,
and type of payment at the index date as potential con-
founders. Men endorse nonmedical use of opioid pre-
scriptions more frequently than women,1 and subjects
on opioids and concomitant benzodiazepines have a
higher risk of having diagnoses of drug dependence.15
How the subjects paid for the opioid at the index date
is an indicator of access to health care and a proxy forsocioeconomic status. Socioeconomic status has been
linked to the risk of drug abuse.13 The types of payments
were cash, Medicaid, and third party, which includes
commercial insurance and Medicare. These variables
were not included in the matching as it would have
substantially increased the difficulty of finding matches.
The effect of these variables was controlled for in the
analysis.Statistical Analysis
To compare the characteristics of the 2 treatment
groups, mean and standard deviation (SD) were calcu-
lated for continuous variables and proportions were
calculated for categorical variables.
Matched analyses were used to compare the risk of
shopping and heavy shopping behavior between tapen-
tadol IR and oxycodone IR. We built conditional logistic
regression models. The grouping variable was the
variable that identified the matches. The outcome was
shopping behavior or heavy shopping behavior, and co-
variates in the logistic models were the treatment group,
gender, type of payment, and prior use of benzodiaze-
pines. Odds ratios (ORs) and 95% confidence intervals
(CIs) were calculated. Subjects with missing data for
any of the matching variables were excluded from
matching. The gender was unknown in less than 1% of
subjects (125) and such a category was created and in-
cluded in the logistic regression models.
Kruskal-Wallis, a nonparametric test, as well as t-tests
and 95% CIs, were used to compare number of shopping
episodes and time to event between tapentadol IR and
oxycodone IR. A chi-square test was used to compare
the type of shopping episodes (ie, percentage of
events inwhich all the prescriptions were for the indexed
opioid).
All analyses were conducted in STATAv.10.1 (StataCorp
LP, College Station, TX). Because this study used com-
pletely anonymized data and did not involve patient
contact, institutional review board approval was not
required.Results
A total of 42,940 eligible subjects exposed to tapenta-
dol werematched to 112,821 eligible subjects exposed to
oxycodone; 13,937 eligible subjects exposed to tapenta-
dol could not bematched to any eligible subject exposed
to oxycodone. Fig 1 depicts the flow of subjects in the
study.
The tapentadol and oxycodone groups were similar
in age, specialties of the prescribers at the index date,
calendar quarter and year of exposure, and duration
of follow-up. In both groups, primary care prescribers
were the most common prescribers. The tapentadol
group had fewer males, fewer subjects exposed to ben-
zodiazepines, higher number of subjects with commer-
cial insurance, and longer follow-up time (Table 1).
Shopping behaviorwas observed in .8%of the subjects
in the oxycodone group and in .2% of the subjects in the
tapentadol group (Table 2). Heavy shopping behavior
Figure 1. Disposition of subjects in the study.
Table 1. Baseline Characteristics of the Subjects
in the Tapentadol and Oxycodone Groups
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the tapentadol group (.01%) (Table 2). The risk of shop-
ping behavior in the unmatched subjects exposed to
tapentadol was .26%.
After adjusting for gender and benzodiazepine use
while respecting the matches, the risk of shopping be-
havior in the oxycodone IR group was 3.5 times (95%
CI, 2.8 to 4.4) the risk in the tapentadol group. The ad-
justed risk of heavy shopping was also much higher in
the oxycodone group than in the tapentadol group
with OR = 6.9 (95% CI, 2.5 to 19.3) (Table 2).
The number of shopping events during the year was
higher in the oxycodone group than in the tapentadol
group. The first shopping episode was observed earlier
in the oxycodone group than in the tapentadol group
(Table 3). In terms of the type of opioid involved in
the shopping episodes, in the oxycodone group,
28.0% of the shopping events involved exclusively oxy-
codone, whereas in the tapentadol group, .6% of the
shopping events involved exclusively tapentadol. In
the oxycodone group, 11.1% of the shopping events
did not include oxycodone, whereas in the tapentadol
group, 69.1% of the shopping events did not include
tapentadol.OXYCODONE IR TAPENTADOL IR
Participants, n 112,821 42,940
Age in years, mean (SD) 51.5 (14.9) 50.1 (14.9)
Men, n (%) 54,450 (48.3) 16,002 (37.3)
History of benzodiazepine
use, n (%)
19,324 (17.1) 5,171 (12.0)
Prescriber specialty, n (%)
Addiction medicine 0 (.0) 0 (.0)
Dentistry 72 (.06) 47 (.1)
Emergency medicine 2,478 (2.2) 946 (2.2)
Surgery 17,559 (15.6) 8,203 (19.1)
Pain medicine 6,406 (5.7) 3,363 (7.8)
Primary care medicine 44,769 (39.7) 15,052 (35.0)
Other 41,537 (36.8) 15,329 (35.7)
Calendar year and quarter of first exposure, n (%)
2009 Q3 10,006 (8.9) 3,461 (8.1)
2009 Q4 12,964 (11.5) 4,670 (10.9)
2010 Q1 14,393 (12.8) 5,276 (12.3)
2010 Q2 19,906 (17.6) 7,532 (17.5)
2010 Q3 24,648 (21.8) 9,422 (21.9)
2010 Q4 30,904 (27.4) 12,579 (29.3)
Active in database, days (SD) 252.5 (135.0) 270.6 (127.2)
Type of payment, n (%)
Cash 16,532 (14.6) 3,332 (7.8)
Medicaid 7,259 (6.4) 1,046 (2.4)
Third party 89,030 (78.9) 38,562 (89.8)Discussion
The risk of shopping behavior was substantially lower
with tapentadol IR than with oxycodone IR. Subjects ex-
posed to tapentadol were less likely to shop, and they
also developed shopping behavior later and had fewer
shopping episodes than the oxycodone subjects. The
lower risk of shopping behavior of tapentadol may be
due to its dual mechanism of action and relatively low af-
finity for the mu receptor.
Subjects in the tapentadol group rarely shopped for
tapentadol, in contrast to oxycodone subjects who of-
ten shopped for oxycodone. Although this finding
could suggest that subjects found oxycodone more
desirable than tapentadol, it also could reflect the
market—oxycodone is more commonly prescribed
than tapentadol and subject to lower copays than ta-
pentadol.
The definition of shopping behavior used in this study
required the overlapping of prescriptions written by dif-
ferent prescribers. One concern is that the overlap could
be as small as 1 day. To address this, we conducted a post
hoc analysis in which only subjects who had 5 or moreshopping episodes were considered shoppers. The find-
ingswere evenmore striking; the risk of shopping behav-
ior in the tapentadol group was even lower relative to
that in the oxycodone group.
We used a definition of shopping behavior that mini-
mizes the inappropriate flagging of individuals with le-
gitimate use of opioids (false positive results) and has
been validated using LRx. This database allows capturing
information across states and cash transactions. Because
it is the largest pharmacy database in the U.S., it permit-
ted us to evaluate a very large number of subjects ex-
posed to tapentadol IR or oxycodone IR. Such a sample
sizewould be very difficult to obtain in any other setting.
In this study, subjects were followed for a year, mean-
ing that all pharmacy transactions for tapentadol IR or
oxycodone IR within that year were assessed. However,
since this is a retrospective database study, not all the
subjects remained in the database for a year (eg, some
could have changed to a pharmacy that is not among
Table 2. Risk of Shopping and Heavy Shopping Behavior
OXYCODONE IR TAPENTADOL IR
MATCHED BUT NOT OTHERWISE
ADJUSTED OR (95% CI)
*MATCHED AND ADJUSTED
OR (95% CI)
Number of subjects 112,821 42,940 — —
Number of subjects who exhibited
shopping behavior (%, 95% CI)
967 (.86, .80–.91) 88 (.20, .16–.25) 3.9 (3.1 to 4.9) 3.5 (2.8–4.4)
Number of subjects who exhibited
heavy shopping behavior (%, 95% CI)
80 (.07, .06–.09) 4 (.01, .0025–.02) 7.4 (2.7–20.4) 6.9 (2.5–19.3)
*Taking matching into account and controlling for gender, benzodiazepine use, and type of payment at the first opioid exposure using a conditional logistic regression.
162 The Journal of Pain Doctor Shopping for Tapentadol and Oxycodonethe 65% of U.S. pharmacies covered by this database).
The follow-up was similar in the tapentadol group, so
differential follow-up cannot explain the lower risk of
shopping behavior observed in the tapentadol group.
This study illustrates the advantage of using a very spe-
cific definition of shopping behavior for research pur-
poses to avoid misclassification of the outcome and to
increase the likelihood of detecting a true difference in
shopping behavior between opioid medications. How-
ever, 1 consequence of adopting a strict definition of
shopping behavior is that the absolute risk of shopping
study is likely to be underestimated.
Shopping behavior is of interest in its own right. Some
readers may see it as being of greater interest as a surro-
gate marker for abuse or diversion of prescribed opioids.
To the extent that shopping behavior is viewed in this
way, we should point out that abuse and diversion of
prescribed opioids is likely to be more common than is
shopping behavior as defined in this study because
they can occur without shopping. In addition, though
some definitions of doctor shopping have been explicitly
linked to opioid abuse,30 the definition used in the cur-
rent study has not been explicitly linked to abuse.
The LRx database does not contain information on
medical conditions, so we could not control for pain
diagnosis or any other medical conditions that might
confound the results. However, we did control for the
type of prescriber and use of benzodiazepines. The
type of prescriber was considered a proxy for the type
and duration of pain. For example, dentists often serve
subjects with acute pain and pain specialists often serve
subjects with chronic pain. The use of benzodiazepines
was considered a proxy for the presence of comorbidities
associated with higher risk of abuse. For example, sub-
jects with posttraumatic stress disorder often are ex-
posed to benzodiazepines.22,26
More subjects in the tapentadol group had insurance
and fewer hadMedicaid. This suggests that they had dif-Table 3. Characteristics of the Shopping Events in
Mean number of shopping events per subject 6 SD
Mean number of shopping events per subject who exhibited shopping beh
Time to event* (mean days [SD])
Episodes (%) in which all prescriptions in the events were for the index dru
Episodes (%) in which none of prescriptions in the events were for the ind
Episodes (%) in which at least 1 prescription was for the index drug
*Using Kruskal-Wallis, P = .04.ferent socioeconomic status, and socioeconomic status
has been linked to the risk of drug abuse.13 However,
rates of shopping behavior remained lower among ta-
pentadol users than oxycodone users after adjustment
for type of payment. Subjects were matched on the geo-
graphic area of the pharmacy that dispensed the opioid
at the index date as well. Matching on zip code allowed
us to control for the effect of opioid availability,2 which
has been found as an impactor risk factor, and at least
partially adjust for socioeconomic status as well. We ex-
cluded subjects with an opioid prescription 3 months be-
fore the index date. By focusing the study on subjects
without recent exposure to opioids, we avoided having
an imbalance of subjects with recent history of opioid
abuse. Nonetheless, this is an observational study and
the groups could have had dissimilar distributions of
unmeasured confounders. In view of the size of the ob-
served OR, a confounder would need to be very strongly
associated with both the exposure and the outcome to
explain the results of the present study.
Tapentadol IR was launched in June of 2009 and has
been on the U.S. market for much less time than oxyco-
done IR. A case could be made that forces in place for
fostering the nonmedical use of oxycodone are stronger
than the ones in place for fostering the nonmedical use
of tapentadol. For instance, there might have not
been enough time for abusers to experiment with tapen-
tadol. Data from the Researched Abuse, Diversion and
Addiction-Related Surveillance, a surveillance system
that monitors the abuse, misuse, and diversion of pre-
scription opioids, suggest that abuse can be seen very
soon after a new opioid is marketed.9,10 Similarly, it
could be argued that differences in the street price
between tapentadol and oxycodone would make
oxycodone more likely to be diverted. The street price
of tapentadol is much lower than the street price of
oxycodone, about 10 cents per milligram of tapentadol
versus 1 dollar per milligram of oxycodone.27 On thethe Oxycodone and Tapentadol Groups
OXYCODONE IR TAPENTADOL IR DIFFERENCE (95% CI)
.02 6 .3 .004 6 .1 .015 (.01–.02)
avior 6 SD 2.1 6 2.6 1.8 6 1.9 .30 (.2–.8)
156.1 6 100.9 180.4 6 104.6 24 (46.4 to 2.2)
g 582 (28.0) 1 (.6) P < .001
ex drug 231 (11.1) 112 (69.1)
1,266 (60.9) 49 (30.2)
Cepeda et al The Journal of Pain 163other hand, the lower street price of tapentadol could
reflect a lower desirability and demand for tapentadol
among abuser populations.27 Definitive proof for the
lower abuse potential of tapentadol will need to await
longer experience with tapentadol, because the desir-
ability of an opioid can change over time.11
It could be also argued that the lower frequency of
shopping behavior observed with tapentadol is due to
inadequate pain relief or poor tolerability. Randomized
controlled trials for acute and chronic pain conditions
have shown that at equianalgesic doses tapentadol
IR and oxycodone IR have comparable efficacy, with ta-
pentadol having superior gastrointestinal tolerability.12
Moreover, lack of analgesia or lack of tolerability withtapentadol will likely place those subjects at a higher
risk of being considered shoppers because they would
more likely have more office visits and more than 1 pre-
scriber.
In summary, this observational study found that sub-
jects exposed to tapentadol IR had a lower risk of shop-
ping behavior than subjects exposed to oxycodone IR.
Its findings are subject to the limitations of observational
studies.Acknowledgment
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